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A genome scan meta-a nalysis (GSMA) was carried out on 32 independent genome-wide
linkage scan analyses that included 3255 pedigrees with 7413 genotyped cases affected with
schizophrenia (SCZ) or related disorders. The primary GSMA divided the autosomes into 120
bins, rank-ordered the bins within each study according to the most positive linkage result in
each bin, summed these ranks (weighted for study size) for each bin across studies and
determined the empirical probability of a given summed rank (PSR) by simulation. Suggestive
evidence for linkage was observed in two single bins, on chromosomes 5q (142–168 Mb) and
2q (103–134 Mb). Genome-wide evidence for linkage was detected on chromosome 2q (119–
152 Mb) when bin boundaries were shifted to the middle of the previous bins. The primary
analysis met empirical criteria for ‘aggregate’ genome-wide significance, indicating that some
or all of 10 bins are likely to contain loci linked to SCZ, including regions of chromosomes 1,
2q, 3q, 4q, 5q, 8p and 10q. In a secondary analysis of 22 studies of European-ancestry samples,
suggestive evidence for linkage was observed on chromosome 8p (16–33 Mb). Although the
newer genome-wide association methodology has greater power to detect weak associations
to single common DNA sequence variants, linkage analysis can detect diverse genetic effects
that segregate in families, including multiple rare variants within one locus or several weakly
associated loci in the same region. Therefore, the regions supported by this meta-analysis
deserve close attention in future studies.
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Introduction
We report here on a new genome scan meta-analysis
(GSMA)1–3 of genome-wide linkage scans (GWLS) of
schizophrenia (SCZ). We previously published a
GSMA of 20 scans that included 1208 pedigrees with
2945 genotyped affected individuals.4 Here we ana-
lyze 32 scans that included 3255 pedigrees with 7413
affected individuals.
Genome-wide association (GWA) study methods
have proven more successful than GWLS for common
diseases: they detect smaller effects of common single
nucleotide polymorphisms (SNPs)5 as well as some
copy number variants (CNVs),6 and have identified
many common disease associations.7 But an ade-
quately powered GWLS can detect a signal from many
kinds of susceptibility variants (common SNPs,
multiple rare SNPs, tandem repeats and heritable
structural variations) in one or more8 loci in a region.
Meta-analysis can achieve much larger sample sizes
than single studies. Consensus linkage regions may
deserve further study using methods such as high-
throughput resequencing.
Family and twin data9 suggest that most of the
genetic risk to SCZ is conferred by multiple interact-
ing loci, each causing a small increase in risk. As SCZ
has similar symptoms and roughly similar prevalence
throughout the world,10 a reasonable hypothesis is
that at least some loci have effects in many popula-
tions. SCZ linkage findings do not replicate consis-
tently, and although there may be some true positives
in small samples from unique populations, in general,
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power is probably limited by inadequate sample size
and differences in ascertainment, marker sets, ances-
try and statistical methods. There must also be some
measurement error due to limitations in diagnostic
methods. Current diagnostic criteria produce the
largest known estimates of heritability (twins) and of
increased risk to first-degree relatives,11,12 and there is
good diagnostic reliability within and across research
groups.13 But diagnostic judgments are based on data
from interview and medical records that vary in
completeness and quality. Fortunately diagnostic
differences are usually among psychotic disorders
that coaggregate in families with similar risks.14 It is
not known whether a further subdivision of cases
would increase power.
We present a GSMA of all 32 scan analyses, and a
secondary analysis of 22 European-ancestry analyses.
The new samples (some of them large) are from
European, non-European and isolate populations, but
are too diverse to consider a subset other than
Europeans. We comment briefly below on an analysis
of heterogeneity between Asian and European sam-
ples. Statistical significance has been evaluated with
permutation tests and simulations. In the primary
analysis, 2 bins met empirical genome-wide criteria
for suggestive linkage; and a set of 10 bins (in eight
chromosomal regions) met an empirical aggregate
criterion for genome-wide significant linkage, indicat-
ing that loci linked to SCZ are present in some or all
of these bins. Five of these bins were consistent with
our previous report.4 When bin boundaries were
shifted to the middle of the previous bins, one
genome-wide significant result was observed on
chromosome 2q, consistent with our previous report.4
Materials and methods
Study selection
We identified GWLS of SCZ (in addition to those
studied previously4) through PubMed literature
searches, conference abstracts and personal contacts
with investigators, selecting the largest analysis for
each study. Study characteristics are summarized in
Table 1. Investigators of each of these studies agreed
to contribute data to this analysis. All scans ascer-
tained probands with SCZ by one of three closely
related sets of diagnostic criteria. Most scans included
relatives with SCZ and those with one or all subtypes
of schizoaffective disorder (SA). A few scans included
only SCZ cases, or included broader diagnoses in
alternative models. Scans were included if informa-
tive families ascertained through a SCZ case had at
least 30 genotyped SCZ and SA cases. We included
only primary genome-wide analyses with few gaps in
marker coverage, and did not consider subsequent
‘fine mapping’ with additional markers or pedigrees
in selected regions. We excluded a small Utah study48
whose RFLP markers were difficult to place on the
current map; a study of a large Costa Rican pedigree49
with too few affected cases; a small study from an
Italian isolate population50 that combined SCZ and
bipolar cases; and a study of isolated villages in
Daghestan51 that used a very broad phenotype defini-
tion. We lacked detailed results for the Icelandic
study of Stefansson et al.52 We included two earlier
studies of Icelandic families for which we had
complete results,15,20 and discuss below a secondary
analysis substituting results from Stefansson et al.
inferred from published graphs.
A companion paper38 reports on a combined
analysis of studies 24–31 (Table 1). Older data for
all or parts of six of those data sets were included as
separate scans in our previous GSMA, so all eight are
treated separately here using the newer data.38 To
eliminate sample overlap, investigators provided us
with data for NUH (study 28) that excluded families
that were also in the US/International study (study 9);
and data for sample 15 (US/Sweden) without families
in sample 26 (Cardiff). The investigators determined
from genotypes that there were no overlapping
families in samples 10 and 22.
There were 14 studies of European-ancestry pedi-
grees (including partial isolates such as Finland and
Ashkenazim); 8 of both European and non-European
families; and 10 non-European samples, including 3
Asian (Japanese, Han Chinese and Indonesian), 2
Latino, 1 Arab, 2 Pacific Island isolates (Palau and
Kosrae) and 2 entirely (study 20) or predominantly
(study 6) African-American samples. Study 6 (Texas)
included a few European-ancestry families for which
we lacked separate data. The ALL analysis included
all 32 samples; the EUR (European-ancestry) analysis
included 22 samples or subsamples (Table 1). Data for
chromosome X markers were available for 23 studies,
so this chromosome was considered in a secondary
analysis.
Linkage scores were obtained from investigators or
internet postings. Data for each study were rank
ordered based on the designated ‘primary’ analysis,
and if this included more than one test or model, we
took the most positive linkage score across tests for
each chromosomal bin. From our previous GSMA,4
data were carried over unchanged for studies 1–10 in
Table 1; the Utah study48 was omitted as discussed
above; and nine studies were updated with new
genotyping results, some with larger samples. Studies
13 and 24–31 used SNP markers from the Illumina
version 4 panel; all other studies used microsatellite
markers at approximately 8–10 cM density.
Marker mapping
Marker locations were determined from the Rutgers
combined linkage map (Build 36),53 or interpolated
based on physical position, other maps or flanking
markers. Chromosomes were divided into bins of
approximately equal genetic widths—120 30-cM bins
(our primary analysis), or (for secondary analyses) 179
20-cM bins and 88 40-cM bins. Six additional 30-cM
bins were defined on the X chromosome (female map
length). If a study had no marker in a bin (for example,
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Table 1 Genome-wide linkage scan characteristics (ALL and European-ancestry analyses)
Study site or projecta ALL analysis EUR analysis
(previous(p)/modified(m)/new(n)) Diagnostic criteriab Ped Aff Ped Aff Markers Program Statistics Ethnicityc
1 Kiel15 (p) SCZ, SA (RDC or D3R) 5 37 5 37 413 WRPC P-values Icelandic
2 Palau16 (p) SCZ, SAS (RDC) 5 33 496 LINKAGE LOD Palau
3 Canada17 (p) SCZ, SA (D3R) 22 79 22 79 381 FASTLINK HLOD Celtic Canada
4 Finland—isolate18 (p) SCZ; þSA (D4) 53 117 53 117 345 MLINK LOD Finnish
5 Finland—national18 (p) SCZ; þSA (D4) 185 394 185 394 345 MLINK LOD Finnish
6 Texas19 (p) SCZ (D4) 27 66 406 Genehunter Plus NPL AA, few EA
7 UC London20 (p) SCZ,SA,UFP (RDC) 13 56 13 56 365 MFLINK P-values Icelandic
8 North Sweden21 (p) SCZ;þSAD;þPNOS;þSAB (D4) 1 43 1 43 371 LINKAGE LOD Swedish
9 US/International22 (p) SCZ, SA (D3R) 294 669 294 669 396 Mapmaker/Sibs MLS EA (inc Chile)
10 Costa Rica23 (p) SCZ, SA (D4) 60 157 404 Genehunter Plus KCLOD Costa Rican
11 Kosrae24 (n) SCZ, SA (D4) 9 30 398 FASTLINK LOD Kosrae
12 Israeli Arab25 (n) SCZ, SAD (D4) 21 59 350 Allegro NPL Arab
13 Japan26 (n) SCZ, SA (D4) 236 488 5861 Merlin KCLOD Japanese
14 Ashkenazi27 (n) SCZ, SA (D4) 29 59 29 59 382 Genehunter LOD Ashkenazi
15 US/Sweden28 (m) SCZ, SA (D4) 135 198 135 198 392 Mapmaker/Sibs MLS Swedish, US
16 Portugal29 (n) SCZ, SAD (D4) 28 67 28 67 366 Genehunter NPL Portuguese
17 South Africa30 (n) SCZ, SAD (D4) 34 62 34 62 388 Merlin KCLOD Afrikaner
18 Eastern Quebec31 (n) SCZ (D3R) 15 71 15 71 350 FASTLINK LOD Quebecois
19 VA (EA)32 (n) SCZ, SAD (D3R) 61 135 61 135 414 Merlin KCLOD EA
20 VA (AA)32 (n) SCZ, SAD (D3R) 60 143 414 Merlin KCLOD AA
21 MGS33 (n) SCZ, SA (D4) 409 924 263 571 400 Genehunter Plus Zlr EA, AA
22 US/Mexico/Central America34 (n) SCZ, SA (D4) 96 240 404 Merlin KCLOD Mexican,Cent Am
23 Taiwan35 (n) SCZ (D4) 557 1207 286 Merlin Zlr Han Chinese
24 Aust/US36–38 (m) SCZ, SA (D3R) 59 143 49 114 5868 Allegro Zlr EA, AA, Other
25 UWA/Bonn38,39 (m) SCZ, SA (D3R) 96 212 96 212 5868 Allegro Zlr German,Israeli
26 Cardiff28,38 (m) SCZ, SA (D3R) 113 239 113 239 5868 Allegro Zlr UK
27 France/LaRe´union38,40,41 (n) SCZ, SA (D3R) 63 186 29 75 5868 Allegro Zlr EA, AA, Other
28 NUH38,42 (n) SCZ, SA (D3R) 20 42 19 40 5868 Allegro Zlr EA, AA
29 Johns Hopkins38,43 (m) SCZ, SA (D3R) 133 317 124 295 5868 Allegro Zlr EA, AA, Other
30 NIMH38,44,45 (m) SCZ, SA (D3R) 106 261 61 142 5868 Allegro Zlr EA, AA, Other
31 VCU/Ireland38,46 (m) SCZ, SAPO (D3R) 184 417 184 417 5868 Allegro Zlr Irish
32 UWA/Indonesia38,47 (n) SCZ (D3R) 124 267 400 Genehunter MLS Indonesian
Total 3283 7476 1835 4141
aSorted by year of publication of the data used in this analysis. The letter in parentheses indicates whether the dataset was included in the previous analysis (p), has
been modified with new genotyping and/or additional pedigrees (m), or is new (n).
bD3R = DSM-IIIR criteria; D4 = DSM-IV criteria; RDC = Research Diagnostic Criteria; SA = schizoaffective disorder (SAS = RDC mainly schizophrenic type;
SAD = depressed type; SAB = bipolar type; SAPO = poor outcome; PNOS = psychosis not otherwise specified; UFP = unspecified functional psychosis (RDC). Diagnoses
separated by commas constitute one model; sets separated by semicolons are alternative models over which scores were maximized, with ‘þ ’ indicating that diagnoses
were added to the ones in the next narrower model.
cEA = mixed European ancestry (usually from the US, but also mixed US, European and Australian samples); AA = African American.
Other abbreviations: Ped = informative pedigrees; Aff = genotyped affected cases. VA = US Veterans’ Administration; MGS = Molecular Genetics of Schizophrenia
collaboration; Aust/US = Australia/US collaboration; NUH = NorthShore University HealthSystem Research Institute; NIMH = National Institute of Mental Health
Schizophrenia Genetics Initiative; VCU = Virginia Commonwealth University; UWA = University of Western Australia. LOD = log of the odds ratio under one or more
parametric models; HLOD = heterogeneity LOD scores (generally, maximized over at least two models); NPL = nonparametric linkage Z-score; MLS = maximum LOD
score (affected sib-pair analysis, constrained to possible triangle); Zlr = Z-likelihood ratio statistic; KCLOD = Kong-Cox equivalent LOD score computed from Zlr.
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the narrower 20 cM bins), we used the mean linkage
score for the two flanking markers, or the single
closest marker for an empty telomeric bin. Bin
boundaries in cM and Mb are listed in online
Supplementary Table 1.
Statistical analysis
GSMA is a nonparametric method to combine data
generated with different maps and statistical tests.1–3
A GSMA divides the genome into approximately
equal-width bins (Nbins), labeled ch.K, where
ch = chromosome and K = bin number (that is, 1.4 is
the fourth bin of chromosome 1). For each study, bins
are ranked by their highest LOD, NPL or Z score or
minimum P-value. Ranks for each sample was
weighted by the square root of the number of
genotyped affected cases, and then, for comparison,
analyzed without weights (results of unweighted
analyses are provided in the online Supplementary
Materials). Note that ‘120’ was the best rank, and
higher summed ranks indicate stronger evidence for
linkage (whereas in our previous report,4 ‘1’ was the
best rank in a study and we reported averaged rather
than summed ranks).
We used GSMA software2 to evaluate nominal (bin-
wise) significance by randomly permuting the ranks
for bins within each study and then resumming the
ranks across studies to determine the empirical
summed rank probability (PSR)—the nominal prob-
ability that a bin would achieve or exceed the
observed summed rank under the null hypothesis of
no linkage in the bin. We also determined the
empirical ordered rank P-value (POR—the probability
that the kth highest summed rank achieves or exceeds
an observed summed rank under the null). Thresh-
olds for genome-wide significant and suggestive
evidence for linkage54 were determined empirically
(see below). For the primary analysis, these thresh-
olds were PSR < 0.00037 and PSR < 0.0077 respec-
tively.
Strong linkage signals can cover a wide genetic
region in complex disorders, and often produce high
summed ranks in adjacent bins,1 but GSMA can miss
a weak linkage signal near the boundary of two bins.
Therefore, regions showing suggestive evidence for
linkage were reanalyzed using 20 and 40 cM bin
widths, and using 30 cM bins starting at the midpoint
of the bins used in the primary analysis (Supplemen-
tary Figure 1).
We tested for heterogeneity in study ranks between
three outbred Asian studies (Taiwan, Japan, Indone-
sia) and the 22 EUR studies, using the nonparametric
Wilcoxon rank sum test. We did not test for hetero-
geneity arising from an arbitrary set of studies;55 these
tests detect bins where study ranks have a wider
spread than expected by chance, but they have low
power and do not identify the study subgroups
contributing to the heterogeneity.56 We also carried
out sensitivity analyses, dropping one study at a time
and analyzing the remaining studies with GSMA
(weighted and unweighted analyses, 30 cM bins).
Simulation study of power and significance thresholds
We performed a simulation study to determine: (1)
power; (2) permutation-based estimates of type I error
and (3) aggregate criteria for genome-wide signifi-
cance. Details are provided in Supplementary Online
Materials and in a previous report.1 Briefly, genome-
wide data were simulated for affected sibling pairs
under the assumption of no linkage or assuming a
range of genetic models (1–10 linked bins with locus-
specific sibling relative risks (lS) of 1.15 or 1.3, at the
edge or near the middle of chromosomes), and 1000
replicates of the 32-sample data set (or of alternative
subsets of the data) were created by replacing each
sample with a number of ASPs with roughly compar-
able linkage information.
For estimates of type 1 error, we determined
empirical bin-wise thresholds for genome-wide sug-
gestive linkage (the nominal P-value observed on
average once per GSMA replicate) or genome-wide
significant linkage (the nominal P-value observed on
average in 5% of GSMA replicates).
We also determined criteria for aggregate genome-
wide significant linkage, that is, that the total number
of bins achieving a specified nominal P-value thresh-
old was greater than that observed in 5% of genome-
wide replicates with no linkage present. This criter-
ion was determined for ALL and EUR studies by
establishing a P-value threshold, P0, for which exactly
5% of unlinked replicates had N or more bins with
PSR < P0. P0 was initially set at 0.05, and the number
of unlinked replicates with XN bins achieving PSR
< P0 was tabulated ( for N = 1, 2, 3,y). P0 was then
reduced incrementally until exactly 5% of simula-
tions had at least N bins with PSR < P0, for some value
N. For example, for the primary weighted analysis of
32 studies, the 5% genome-wide threshold by this
procedure was 10 bins with P < 0.046; for EUR
studies, it was 10 bins with P < 0.048.
For power calculations, we determined how often,
on average, the linked bins exceeded the PSR thresh-
old for ALL and for EUR studies, and, to investigate
heterogeneity, for ALL studies assuming that linkage
arose only in EUR studies.
Results
Evidence for linkage (ALL and EUR studies)
Figure 1 illustrates P-values for all bins in the ALL
and EUR analyses, and the figure legend states the
empirical P-value thresholds for each study. For ALL
studies (3255 pedigrees, 7413 genotyped cases),
Table 2 lists the 10 bins (in eight nonadjacent
chromosomal regions) that achieved PSR < 0.05 in
the primary analysis (weighted, 30 cM bins). These 10
bins met the empirical aggregate criterion for genome-
wide significant linkage (10 bins with nominal
PSR < 0.046). Suggestive evidence for linkage
was observed for single bins on chromosome 5q (bin
5.6, PSR = 0.0046) and chromosome 2q (bin 2.5,
PSR = 0.0075). Figure 1 illustrates the results for all
bins (ALL and EUR analyses), and Figure 2 illustrates
Genome-wide linkage studies of SCZ
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the relative ranks of bins in each study. (Results for all
analyses are available in Online Supplementary
Tables; ranks for each study are available online at
www.kcl.ac.uk/mmg/ngdata.html.)
Table 3 summarizes results for 22 EUR samples or
subsamples (1813 pedigrees, 4094 genotyped cases).
Suggestive evidence for linkage was observed on
chromosome 8p (PSR =0.00057, close to the genome-
wide threshold for 22 EUR studies of 0.00044), with a
further five bins in four different regions achieving
nominal significance.
On chromosome X, there were no nominally signi-
ficant bins for ALL studies; there was one such bin (X.5,
130–162 cM, 119–141 Mb, PSR = 0.0247) for EUR studies.
When estimated ranks (interpolated from published
graphs) for the Icelandic study of Stefansson et al.52
were substituted for the results of Gurling et al.20 and
Moises et al.,15 results were similar to those shown in
Table 1 except that bin 3.4 failed to achieve nominal
significance. For EUR studies, results again were
similar except that bins 8.2 and 2.8 both achieved
suggestive significance.
Effect of bin width
Online Supplementary Figures 2–4 illustrate results
of analyses using four alternative bin widths (20, 30
and 40 cM, and 30 cM bins shifted by 50% for
chromosomes with suggestive evidence for linkage
(chromosomes 2 and 5 for ALL, chromosome 8 for
EUR). On chromosome 2, genome-wide significance
was obtained for the shifted 30 cM bin (PSR = 0.00035,
Genomewide significant
Genomewide suggestive
Aggregate significance
0
0.5
1
1.5
2
2.5
3
3.5
4
−−
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
ALL EUR
Figure 1 Genomewide results for primary analysis (weighted, 30 cM bins) for ALL studies (red) and EUR studies (blue). The
two upper dashed lines represent empirical thresholds for genomewide significant (theoretical PSR = 0.00037) and suggestive
(theoretical PSR =0.0077) evidence for linkage for a single bin for ALL studies; and the lower dashed line represents the
threshold for aggregate significance for ALL studies (theoretical PSR = 0.046 in 10 or more bins). The thresholds for EUR
studies were slightly less stringent (PSR values of 0.00044, 0.0078 and 0.0475 (in 10 or more bins) respectively), but the Figure
shows all EUR bins within the region for their correct threshold of significance.
Table 2 Bins achieving nominally significant evidence for
linkage (ALL studies)
Pos Bin cM Mb PSR POR
1 5.6* 148.9–178.7 141.8–167.7 0.00459 0.43156
2 2.5* 117.5–146.9 103.3–134.0 0.00755 0.22798
3 1.6* 143.1–171.7 114.6–162.1 0.00814 0.06639
4 2.8 205.7–235.1 206.3–228.3 0.00916 0.01970
5 2.6* 146.9–176.3 134.0–169.9 0.02395 0.14269
6 1.4 85.8–114.5 57.3–84.6 0.02692 0.08449
7 5.7 178.7–208.5 167.7–180.4 0.02760 0.03430
8 8.2* 28.1–56.2 15.7–32.7 0.03086 0.02070
9 10.6 145.9–175.0 123.1–135.1 0.03487 0.01350
10 3.4 95.9–127.9 71.6–120.2 0.04047 0.01140
Shown are the bins with nominally significant evidence
for linkage (PSR < 0.05), for ALL studies (30 cM bins,
weighted analysis), ordered by their position (1 = best)
according to weighted analysis PSR (summed rank P-value).
POR : ordered rank P-value. Bold PSR values achieved
an empirical threshold for suggestive evidence for linkage
(PSR < 0.0077). No single bin achieved an empirical genome-
wide significant threshold (0.00037).
Empirically (see text), 10 or more bins with nominal PSR
< 0.046 was observed in 5% of simulated replicates of this
dataset in the absence of linkage. Therefore, it is likely that
at least some of the bins listed here contain loci linked to
SCZ. Asterisks indicate which regions were consistent with
our previous GSMA4 of 20 schizophrenia scans (i.e., bins
that overlap with those in the previous analysis that met
aggregate significance criteria—that analysis used the
Marshfield rather than the Rutgers map, so bin boundaries
were not identical). See Figure 2 for further details.
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132.2–161.6 cM, 118.7–152 Mb), and suggestive
linkage evidence was seen in the adjacent bin
(102.8–132.2 cM, 84.9–118.7 Mb). For the region of
chromosome 5q that produced suggestive evidence
for linkage in the primary analysis, the signal was
similar regardless of bin width. On chromosome 8,
using 20 cM bins extended the signal by approxi-
mately 5 cM in both directions; if linkage is
present, this pattern could indicate a broader signal
(multiple loci) or the effects of a single strong signal
on adjacent bins.
Heterogeneity and sensitivity analyses
In tests of differences between 22 EUR vs 3 Asian
studies, none of the 120 bins exceeded nominal
P < 0.01, and only 4 bins achieved nominal P < 0.05,
thus, no significant difference was observed. The
most significant evidence for heterogeneity between
the Asian and European studies was in bin 1.5, but
this did not reach the suggestive threshold (online
Supplementary Figure 5). Results of sensitivity
analyses, omitting each study in turn, are shown in
online Supplementary Figures 6 and 7. The largest
changes: bin 8.2 (8p) achieves the suggestive linkage
threshold without the Taiwan data set; bin 2.8 (2q)
becomes substantially more significant (but not
achieving genome-wide significance) without the
Japan data set; bin 5.6 (5q) becomes substantially
more significant (but not genome-wide significant)
without the Suarez et al. data set (study 21); and bin
6.3 (6pq) would join the list of nominally significant
bins without either the Taiwan or Japan data set.
Type I error
Type I error was calculated for the unlinked GSMA
simulations (120 000 30-cM bins) by determining the
number of observed bins in which the GSMA program
computed PSR values (based on permutation alone)
that were less than the theoretical threshold for
nominal significance (0.05); for genome-wide sugges-
tive linkage, or a value expected once per GSMA
(1/120 = 0.00833) or genome-wide significant linkage
(0.05/120 = 0.00042). The GSMA program’s permuta-
tion procedure produced type I errors that were
slightly liberal for ALL (0.053, 0.0096 and 0.00051)
and less liberal for EUR studies (0.051, 0.0091 and
0.00042). The source of the discrepancy is not clear,
but we have used the permutation-based suggestive
and significant values here for single bins (0.0077 and
0.00037 for ALL, and 0.0078 and 0.00044 for EUR
studies) and an empirical threshold for aggregate
genome-wide significance as described above.
Power
Table 4 summarizes the results of power calculations
from simulation studies. Power is lower for edge bins
for multipoint analyses, so we computed a weighted
average of power assuming 20% edge and 80% mid-
chromosome bins (see Table 4 legend). Power was
excellent to detect significant linkage at multiple loci
with observed population-wide lS = 1.3 (30% in-
creased risk in sibs) across ALL studies or in EUR
studies alone. For lS = 1.15, there was excellent power
to detect significant linkage in multiple bins (for ALL
studies), or to detect suggestive evidence for linkage
in multiple bins (if limited to EUR studies); there was
reduced power in the presence of substantial hetero-
geneity. Genetic effects limited to a defined subset
(EUR) were more readily detected in a separate
analysis.
Discussion
Meta-analysis of 32 GWLS, encompassing 7413
individuals affected with SCZ or related disorders
in 3255 pedigrees, produced evidence for significant
linkage in the genome based on empirical aggregate
criteria: 10 30-cM bins that achieved bin-wise
Table 3 Bins achieving nominally significant evidence for
linkage (European studies)
Pos Bin cM Mb PSR POR
1 8.2* 28.1–56.2 15.7–32.7 0.00057 0.06659
2 2.8 205.7–235.1 206.3–228.3 0.01016 0.35077
3 5.6* 148.9–178.7 141.8–167.7 0.01718 0.33717
4 16.2* 33.3–66.7 13.2–51.5 0.01775 0.15808
5 3.4 95.9–127.9 71.6–120.2 0.04359 0.62724
6 6.3* 56.0–84.0 33.9–56.6 0.04433 0.44626
Shown are bins with nominally significant evidence for
linkage (PSR < 0.05), in 22 samples or subsamples of
European-ancestry families (see Table 1); the bolded
p-value met empirical criteria for suggestive evidence for
linkage (PSR < 0.0078). The results here did not meet
aggregate criteria for significant genome-wide evidence for
linkage in this subset of the data (10 bins with nominal
PSR < 0.0475). See legend for Table 2 for additional details.
Figure 2 Ranks by study and summed ranks. Shown for
each study is the within-study rank of each bin. ‘1’ against a
red background indicates bins with ranks of 116–120 (the
bin containing the most significant linkage score in a study
is ranked 120); 2 indicates ranks 111–115; 3—ranks
101–110; 4—ranks 81–100; 5—ranks 61–80; 6—ranks 41–
60; 7—ranks 21–40; and 8—ranks 1–20 (cells with 7 and 8
have a white background). Shown at the top of each part of
the figure are the bin number, the weighted summed rank
for each bin across studies (i.e., weighted for each sample by
the square root of the N of genotyped affected individuals),
and the rank-ordered position of that bin in the ALL
analysis (i.e., 1 is the best position, see details in Table 2).
Purple background indicates bins with empirical suggestive
evidence for linkage in the ALL analysis; 10 bins shaded in
purple, yellow or blue met the threshold for aggregate
genome-wide evidence for linkage (10 bins with nominal
P < 0.046); and bin 8.2 (shaded blue) also met empirical
suggestive evidence for linkage in the EUR analysis. Shown
at the bottom is the distal boundary of each bin in Rutgers
cM and in Mb (build 36). Note that tied ranks can result in
uneven numbers of bins in a grouping, particularly for
lower ranks when there are many zero or negative scores.
See Table 1 for the references associated with each study.
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PSR < 0.046. Genome-wide evidence for linkage was
detected on chromosome 2q (118.7–152 Mb) in a
secondary analysis that shifted bin location by 50%,
consistent with our previous finding of significant
linkage in the same region in our previous GSMA of
20 studies.4 Suggestive evidence for linkage was
detected in ALL studies in two single bins, on
chromosomes 5q and 2q. Separate analysis of Eur-
opean-ancestry samples produced linkage evidence
falling just short of the genome-wide significance in
bin 8.2 (15.7–32.7 Mb).
It is widely assumed that many loci contribute
to SCZ susceptibility. Table 4 shows that for the
GSMA method, power to detect at least one true
linkage goes up with the number of linked loci, but
the power to detect any specific locus decreases,
because in a rank-ordered test there is a finite number
of high ranks in each study. But if there were many
loci with locus-specific lS values of 1.3 or even 1.15
(averaged across all study populations and account-
ing for the effects of various sources of measurement
error), we would expect to detect genome-wide
significant linkage in several individual bins, and
suggestive evidence for linkage in many more than
two bins. It would be reasonable to conclude that
there are probably no loci with such strong effects
worldwide or across all European populations,
although they might exist within particular popu-
lations for which samples of this size are not available
or within subsets of families, which we cannot yet
identify in advance.
The power of linkage analysis for a locus is
predicted by its contribution to the relative risk (RR)
to siblings of probands (lS),57 whereas the power of
association analysis is predicted by allelic or geno-
typic RRs, that is, the increased risk to individual
carriers.5 GWA studies have produced robust associa-
tion findings for many complex genetic disorders58–60
typically with RRs of 1.1–1.5. A variant found on 10%
of chromosomes conferring a ‘large’ RR of 1.5 per
allele in a multiplicative model (2.25 for homozygous
carriers) would produce a population-wide sibling RR
of only 1.02 (undetectable by linkage). But GWA chips
are unlikely to tag all pathogenic variants. For
example, in NOD2 there are three rare variants, each
with a frequency of less than 5%, that confer
moderate risks of Crohn’s disease. Their individual
effects generate only weak signals when assayed by
the Affymetrix 500K chip because they are poorly
tagged; but combined, they confer a sibling RR of 1.16,
which is detectable in a very large linkage sample.58,61
This illustrates a strength of linkage analysis: allelic
heterogeneity is difficult to detect in association
studies, as the genetic effect is split across variants,
but linkage can detect the pooled effect of all variants
(not only SNPs) within one or more susceptibility
genes or elements in a region.
Readers may be interested to know the location of
SCZ candidate genes or regions in relation to bins that
produced evidence for linkage here. On chromosome
1q, NOS1AP (160 Mb; previously known as CA-
PON),62,63 RGS4 (161.3 Mb)64,65 and UHMK1
(160.7 Mb)66 are near the telomeric edge of bin 1.6
(114.6–162.1 Mb), and the rare (usually de novo) SCZ-
associated CNV is located in a different part of the
same bin (145–146 Mb).67,68 On chromosome 8p,
PPP3CC (22.35 Mb)69 and NRG1 (31.6–32.7 Mb)52,70
are both within bin 8.2 (15.7–32.7 Mb). On chromo-
some 2q, ZNF804A, which contains a SNP that
produced genome-wide significant evidence for asso-
ciation in a combined SCZ-bipolar disorder sample,71
is in bin 2.7 at 185 Mb. This bin was not nominally
Table 4 Power to detect linkage in simulation studies (weighted GSMA)
Level of significance
Nominal Suggestive Genome-wide
Number of linked bins: 1 5 10 1 5 10 1 5 10
l S = 1.3
ALL studies 1.000 1.000 1.000 1.000 1.000 0.998 1.000 0.996 0.975
European samples 1.000 0.998 0.993 1.000 0.992 0.953 0.950 0.912 0.745
ALL, Heterogeneitya 0.988 0.952 0.918 0.898 0.834 0.705 0.600 0.474 0.325
l S = 1.15
ALL studies 1.000 1.000 0.989 0.996 0.980 0.932 0.904 0.850 0.705
European samples 0.970 0.948 0.908 0.874 0.822 0.697 0.598 0.468 0.323
ALL, Heterogeneitya 0.864 0.774 0.740 0.592 0.546 0.403 0.186 0.180 0.116
Shown is the power of weighted GSMA to detect linkage in the simulation study of samples of affected sibling pairs with
information approximately comparable to the 32 studies in the schizophrenia GSMA (120 30-cM bins). lS = relative risk to
siblings of case probands vs population risk. For 1 linked bin per simulated genome, power is a weighted average assuming
that 20% of bins lie at a chromosome end (‘edge,’ see text), and 80% of are mid-chromosomal (‘mid’). Simulations with 5
linked loci included 1 edge and 4 mid bins; those with 10 linked included 2 edge and 8 mid bins.
aHeterogeneity analyses modelled cases where all samples were included, but European samples were linked as shown while
non-European studies were unlinked.
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significant in the primary analysis, but 185 Mb is
within nominally significant bins in two secondary
analyses (one that shifted bin boundaries by 50% and
one that considered 40 cM bin widths). DTNBP1,
DAOA, TRAR4/STX7, CHRNA7, COMT/ARVCF,
DISC1, AKT1, HTR2A and DRD2 are not in bins
listed in Tables 2 or 3. Many of the research groups
whose samples are included here are actively
investigating association of SCZ to sequence variants
in genes identified in linkage regions or by the more
recent genome-wide association methodology.
In conclusion, this updated GSMA of 32 SCZ
studies showed significant evidence for linkage on
chromosome 2q in a secondary analysis, suggestive
evidence for linkage on chromosomes 5q and 2q in
the primary analysis, and suggestive evidence for
linkage on 8p in European samples. Genome-wide
significant aggregate evidence for linkage (that is,
more modestly significant results than expected by
chance) was observed based on results for 10 bins in 8
nonadjacent chromosomal regions. As results from
genome-wide association studies emerge, it may be
important to keep in mind that there may be SCZ
susceptibility loci in some of these consensus linkage
regions that cannot be detected by common tag SNPs.
It is likely that diverse methods will be required to
identify specific DNA sequence variants and to
confirm and define their role in the etiology of SCZ.
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